A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies
Foreign viral proteins expressed by rabies virus (RV) have been shown to induce potent humoral and cellular immune responses in immunized animals. In addition, highly attenuated and, therefore, very safe RV-based vectors have been constructed. Here, an RV-based vaccine vehicle was utilized as a novel vaccine against severe acute respiratory syndrome coronavirus (SARS-CoV). For this approach, the SARS-CoV nucleocapsid protein (N) or envelope spike protein (S) genes were cloned between the RV glycoprotein G and polymerase L genes. Recombinant vectors expressing SARS-CoV N or S protein were recovered and their immunogenicity was studied in mice. A single inoculation with the RV-based vaccine expressing SARS-CoV S protein induced a strong SARS-CoV-neutralizing antibody response. The ability of the RV-SARS-CoV S vector to confer immunity after a single inoculation makes this live vaccine a promising candidate for eradication of SARS-CoV in animal reservoirs, thereby reducing the risk of transmitting the infection to humans.
AubertM. F. A.,
MassonE.,
ArtoisM.,
BarratJ.1994; Oral wildlife rabies vaccination field trails in Europe with recent emphasis on France. In Lyssaviruses pp 219–243 Edited by
RupprechtC. E.,
DietzscholdB.,
KoprowskiH.
Berlin, Heidelberg, New York: Springer;
DrostenC.,
GuntherS.,
PreiserW.23 other authors2003; Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 348:1967–1976[CrossRef]
FoleyH. D.,
McGettiganJ. P.,
SilerC. A.,
DietzscholdB.,
SchnellM. J.2000; A recombinant rabies virus expressing vesicular stomatitis virus glycoprotein fails to protect against rabies virus infection. Proc Natl Acad Sci U S A 97:14680–14685[CrossRef]
FoleyH. D.,
OteroM.,
OrensteinJ. M.,
PomerantzR. J.,
SchnellM. J.2002; Rhabdovirus-based vectors with human immunodeficiency virus type 1 (HIV-1) envelopes display HIV-1-like tropism and target human dendritic cells. J Virol 76:19–31[CrossRef]
GuanY.,
ZhengB. J.,
HeY. Q.15 other authors2003; Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 302:276–278[CrossRef]
McGettiganJ. P.,
FoleyH. D.,
BelyakovI. M.,
BerzofskyJ. A.,
PomerantzR. J.,
SchnellM. J.2001a; Rabies virus-based vectors expressing human immunodeficiency virus type 1 (HIV-1) envelope protein induce a strong, cross-reactive cytotoxic T-lymphocyte response against envelope proteins from different HIV-1 isolates. J Virol 75:4430–4434[CrossRef]
McGettiganJ. P.,
SarmaS.,
OrensteinJ. M.,
PomerantzR. J.,
SchnellM. J.2001b; Expression and immunogenicity of human immunodeficiency virus type 1 Gag expressed by a replication-competent rhabdovirus-based vaccine vector. J Virol 75:8724–8732[CrossRef]
McGettiganJ. P.,
NaperK.,
OrensteinJ.,
KoserM.,
McKennaP. M.,
SchnellM. J.2003a; Functional human immunodeficiency virus type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and env expressed from a single rhabdovirus-based vaccine vector genome. J Virol 77:10889–10899[CrossRef]
McGettiganJ. P.,
PomerantzR. J.,
SilerC. A.,
McKennaP. M.,
FoleyH. D.,
DietzscholdB.,
SchnellM. J.2003b; Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 gag have greatly reduced pathogenicity but are highly immunogenic. J Virol 77:237–244[CrossRef]
MeslinF.-X.,
FishbeinD. B.,
MatterH. C.1994; Rationale and prospects for rabies elimination in developing countries. In Lyssaviruses pp 1–26 Edited by
RupprechtB. D. C. E.,
KoprowskiH.
Berlin, Heidelberg, New York: Springer;
MorimotoK.,
FoleyH. D.,
McGettiganJ. P.,
SchnellM. J.,
DietzscholdB.2000; Reinvestigation of the role of the rabies virus glycoprotein in viral pathogenesis using a reverse genetics approach. J Neurovirol 6:373–381[CrossRef]
MorimotoK.,
SchnellM. J.,
PulmanausahakulR.,
McGettiganJ. P.,
FoleyH. D.,
FaberM.,
HooperD. C.,
DietzscholdB.2001b; High level expression of a human rabies virus-neutralizing monoclonal antibody by a rhabdovirus-based vector. J Immunol Methods 252:199–206[CrossRef]
OrciariL. A.,
NiezgodaM.,
HanlonC. A.,
ShaddockJ. H.,
SanderlinD. W.,
YagerP. A.,
RupprechtC. E.2001; Rapid clearance of SAG-2 rabies virus from dogs after oral vaccination. Vaccine 19:4511–4518[CrossRef]
PeirisJ. S.,
LaiS. T.,
PoonL. L. 14 other authors; 2003; Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361:1319–1325[CrossRef]
RotaP. A.,
ObersteM. S.,
MonroeS. S.32 other authors2003; Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300:1394–1399[CrossRef]
RupprechtC. E.,
HanlonC. A.,
NiezgodaM.,
MurphyS.,
SchnellM. J.,
DietzscholdB.2001; Oral rabies vaccination of the mongoose, Herpestes auropunctatus
. In Rabies in the Americas. XII International Meeting on Advances in Rabies Research and Control in the Americas Peterborough, Ontario, Canada:
SchnellM. J.,
FoleyH. D.,
SilerC. A.,
McGettiganJ. P.,
DietzscholdB.,
PomerantzR. J.2000; Recombinant rabies virus as potential live-viral vaccines for HIV-1. Proc Natl Acad Sci U S A 97:3544–3549[CrossRef]
SilerC. A.,
McGettiganJ. P.,
DietzscholdB.,
HerrineS. K.,
DubuissonJ.,
PomerantzR. J.,
SchnellM. J.2002; Live and killed rhabdovirus-based vectors as potential hepatitis C vaccines. Virology 292:24–34[CrossRef]
SubbaraoK.,
McAuliffeJ.,
VogelL. 7 other authors; 2004; Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. J Virol 78:3572–3577[CrossRef]
WiktorT. J.,
MacfarlanR. I.,
FogginC. M.,
KoprowskiH.1984; Antigenic analysis of rabies and Mokola virus from Zimbabwe using monoclonal antibodies. Dev Biol Stand 57:199–211
YangZ. Y.,
KongW. P.,
HuangY.,
RobertsA.,
MurphyB. R.,
SubbaraoK.,
NabelG. J.2004; A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 428:561–564[CrossRef]
A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies